DelNova has announced a partnership with Pace® Life Sciences to serve as its contract development and manufacturing organization (CDMO). This collaboration will enable DelNova to advance the clinical development of its lead candidate, ReViVox®, designed to mitigate adverse effects that may occur following botulinum neurotoxin (BoNT) treatments such as Botox®. BoNTs encompass several well-known U.S. brands, including BOTOX®, DYSPORT®, XEOMIN®, and JEUVEAU®.

Pace® Life Sciences brings critical expertise to the table, facilitating the IND (investigational new drug) research necessary for future FDA submissions, encompassing formulation, kinetics, and stability assessments.

DelNova is actively pursuing both dilutive and non-dilutive funding options, including a recently submitted application to the SBIR (Small Business Innovation Research) program.

Moreover, this partnership equips DelNova with the capability to manufacture small GMP (Good Manufacturing Practice) batches of drug products tailored for clinical studies. Pace® Life Sciences boasts facilities across the United States, including a specialized CDMO facility in San Diego, renowned for its proficiency in complex drug delivery, formulation, and sterile fill-finish GMP manufacturing.

Mary Gardner, CEO and Founder of DelNova, along with Frank Tagliaferri, PhD, Vice President of Pharmaceutical Development at Pace® Life Sciences, expressed their excitement about reuniting to tackle this groundbreaking endeavor. Both Gardner and Tagliaferri bring decades of pharmaceutical development experience to DelNova's mission. Currently, there is no product available to counteract unwanted paralysis induced by BoNTs. ReViVox® holds the potential to be a pioneering solution addressing this unmet medical need.